Berkshire Biomedical Corporation is a privately held medical device company. Berkshire is pioneering the use of biometric technologies, combined with cloud-based and physician-enabled remote management systems, to provide precise and accurate personalized medication delivery to only the Authenticated Intended User (AIU™). The Company’s lead product under development, the Computerized Oral Prescription Administration System (COPA™), is a hand-held, automated, personalized oral liquid dispensing system designed and intended to deliver controlled and non-controlled liquid oral medications to only the Authenticated Intended User upon confirmation of dual biometric identifications (fingerprint and dentition). Upon receiving regulatory authorization, the Company intends to initially seek opportunities to leverage COPA in the delivery and remote management of oral liquid medication methadone, for Medication Use for Opioid Use Disorder treatment (MOUD) and then subsequently for the delivery of controlled medications for the treatment of pain, as they have the greatest need for the benefits of COPA’s features. The COPA™ System is currently under development, has NOT been reviewed by the U.S. Food and Drug Administration and is not available for commercial sale.